These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21645370)

  • 1. Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice.
    Dow GS; Milner E; Bathurst I; Bhonsle J; Caridha D; Gardner S; Gerena L; Kozar M; Lanteri C; Mannila A; McCalmont W; Moon J; Read KD; Norval S; Roncal N; Shackleford DM; Sousa J; Steuten J; White KL; Zeng Q; Charman SA
    Malar J; 2011 Jun; 10():150. PubMed ID: 21645370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of a prodrug approach to minimize potential CNS exposure of next generation quinoline methanols while maintaining efficacy in in vivo animal models.
    Sousa JC; Milner E; Carroll D; McCalmont W; Gardner S; Moon J; Johnson JD; Lee P; Auschwitz J; Roncal N; Caridha D; Tungteung A; Zeng Q; Reyes S; Smith B; Li Q; Kozar MP; Melendez V; Dow G
    Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):231-6. PubMed ID: 24705994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols.
    Milner E; McCalmont W; Bhonsle J; Caridha D; Cobar J; Gardner S; Gerena L; Goodine D; Lanteri C; Melendez V; Roncal N; Sousa J; Wipf P; Dow GS
    Malar J; 2010 Feb; 9():51. PubMed ID: 20149249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
    Gutman J; Green M; Durand S; Rojas OV; Ganguly B; Quezada WM; Utz GC; Slutsker L; Ruebush TK; Bacon DJ
    Malar J; 2009 Apr; 8():58. PubMed ID: 19358697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate.
    Na-Bangchang K; Ruengweerayut R; Wernsdorfer WH
    Eur J Clin Pharmacol; 2011 Jul; 67(7):687-91. PubMed ID: 21556929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
    Krudsood S; Looareesuwan S; Tangpukdee N; Wilairatana P; Phumratanaprapin W; Leowattana W; Chalermrut K; Ramanathan S; Navaratnam V; Olliaro P; Vaillant M; Kiechel JR; Taylor WR
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3730-7. PubMed ID: 20547795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose.
    Hellgren U; Berggren-Palme I; Bergqvist Y; Jerling M
    Br J Clin Pharmacol; 1997 Aug; 44(2):119-24. PubMed ID: 9278194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
    Milner E; Gardner S; Moon J; Grauer K; Auschwitz J; Bathurst I; Caridha D; Gerena L; Gettayacamin M; Johnson J; Kozar M; Lee P; Leed S; Li Q; McCalmont W; Melendez V; Roncal N; Sciotti R; Smith B; Sousa J; Tungtaeng A; Wipf P; Dow G
    J Med Chem; 2011 Sep; 54(18):6277-85. PubMed ID: 21854078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum.
    Milner E; Sousa J; Pybus B; Melendez V; Gardner S; Grauer K; Moon J; Carroll D; Auschwitz J; Gettayacamin M; Lee P; Leed S; McCalmont W; Norval S; Tungtaeng A; Zeng Q; Kozar M; Read KD; Li Q; Dow G
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):151-8. PubMed ID: 21751074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses.
    Wernsdorfer WH; Noedl H; Rendi-Wagner P; Kollaritsch H; Wiedermann G; Mikolasek A; Karbwang J; Na-Bangchang K
    Malar J; 2013 Dec; 12():443. PubMed ID: 24321055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.
    Dow GS; Heady TN; Bhattacharjee AK; Caridha D; Gerena L; Gettayacamin M; Lanteri CA; Obaldia N; Roncal N; Shearer T; Smith PL; Tungtaeng A; Wolf L; Cabezas M; Yourick D; Smith KS
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4132-43. PubMed ID: 16966402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.
    Karbwang J; Bunnag D; Breckenridge AM; Back DJ
    Eur J Clin Pharmacol; 1987; 32(2):173-7. PubMed ID: 3495440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mefloquine with dihydroartemisinin as 2-day regimens in patients with uncomplicated falciparum malaria.
    Thuy le TD; Hung le N; Hung NC; Na-Bangchang K
    Southeast Asian J Trop Med Public Health; 2007 Mar; 38(2):205-12. PubMed ID: 17539268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cerebral malaria on brain distribution of mefloquine.
    de Lagerie SB; Fernandez C; German-Fattal M; Gantier JC; Gimenez F; Farinotti R
    Drug Metab Lett; 2009 Jan; 3(1):15-7. PubMed ID: 19356112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
    Guidi M; Mercier T; Aouri M; Decosterd LA; Csajka C; Ogutu B; Carn G; Kiechel JR
    Malar J; 2019 Apr; 18(1):139. PubMed ID: 30999915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination.
    Lai CS; Nair NK; Mansor SM; Olliaro PL; Navaratnam V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):308-14. PubMed ID: 17719858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border.
    Na-Bangchang K; Ruengweerayut R; Mahamad P; Ruengweerayut K; Chaijaroenkul W
    Malar J; 2010 Oct; 9():273. PubMed ID: 20929590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses.
    Gimenez F; Pennie RA; Koren G; Crevoisier C; Wainer IW; Farinotti R
    J Pharm Sci; 1994 Jun; 83(6):824-7. PubMed ID: 9120814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.
    Simpson JA; Watkins ER; Price RN; Aarons L; Kyle DE; White NJ
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3414-24. PubMed ID: 11083649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens.
    Na-Bangchang K; Molunto P; Banmairuroi V; Thanavibul A; Karbwang J
    Int J Clin Pharmacol Res; 1995; 15(5-6):215-20. PubMed ID: 8835620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.